Evofem Biosciences to be Delisted from Nasdaq
Ticker: EVFM · Form: 8-K · Filed: Aug 30, 2024 · CIK: 1618835
Sentiment: bearish
Topics: delisting, nasdaq, compliance
TL;DR
Nasdaq's kicking Evofem off the exchange, trading stops Friday.
AI Summary
Evofem Biosciences, Inc. received a notice on August 28, 2024, indicating it failed to meet the continued listing standards of The Nasdaq Stock Market LLC. The company has been notified that its common stock will be delisted from The Nasdaq Capital Market, with trading expected to cease on August 30, 2024.
Why It Matters
This delisting signifies a significant setback for Evofem Biosciences, potentially impacting its ability to raise capital and its stock's liquidity.
Risk Assessment
Risk Level: high — Delisting from a major stock exchange like Nasdaq poses a severe risk to a company's financial health and investor confidence.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- The Nasdaq Stock Market LLC (company) — Listing Exchange
- August 28, 2024 (date) — Notice Date
- August 30, 2024 (date) — Expected Trading Cessation Date
- Neothetics, Inc. (company) — Former Company Name
FAQ
What is the primary reason for Evofem Biosciences' delisting from Nasdaq?
Evofem Biosciences, Inc. received a notice that it failed to meet the continued listing standards of The Nasdaq Stock Market LLC.
When is Evofem Biosciences' common stock expected to cease trading on The Nasdaq Capital Market?
Trading of Evofem Biosciences' common stock is expected to cease on The Nasdaq Capital Market on August 30, 2024.
What is the exact date of the notice regarding the failure to meet listing standards?
The notice regarding the failure to meet continued listing standards was dated August 28, 2024.
What was Evofem Biosciences' former company name?
Evofem Biosciences, Inc.'s former company name was Neothetics, Inc.
What is the principal executive office address for Evofem Biosciences?
The address of Evofem Biosciences' principal executive offices is 7770 Regents Road, Suite 113-618, San Diego, California 92122.
Filing Stats: 820 words · 3 min read · ~3 pages · Grade level 12.8 · Accepted 2024-08-30 17:04:02
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share EVFM OTCQB Indicate by
- $0.01 — or the Company's common stock was below $0.01 per share for 30 consecutive trading da
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-034623.txt ( ) — 206KB
- evfm-20240828.xsd (EX-101.SCH) — 3KB
- evfm-20240828_lab.xml (EX-101.LAB) — 33KB
- evfm-20240828_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: August 30, 2024 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer